Using hormone replacement therapy (HRT) to reduce cardiovascular risk during menopause remains a topic of debate. The ...

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Most of these new drugs work by silencing the instructions from the LPA gene so a protein that is a key part of Lp(a) cholesterol isn’t produced. Muvalaplin works differently. It interferes ...

Two therapeutic approaches to Lp(a) lowering are currently under investigation. Injectable RNA-based therapies that prevent translation of LPA messenger RNA may block the production of ApoA used ...

Approximately one in five people worldwide has elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke. 1 The Roche Diagnostics ...

determined by genetic variations in the LPA gene.2 Raised Lp(a) is particularly prevalent among people of African descent and can increase in women following menopause.5,6 High levels of Lp(a ...

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...

LPA, a gene associated with lipoprotein(a), emerged as a novel risk factor for AMD. This is the first study to link LPA to AMD, suggesting a role in drusen formation. Reliance on retrospective ...